Roche Touts Benefit Of Health Economic Data For Targeted Cancer Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
Reimbursement for Genentech's Avastin indicates the value of health economic data, Roche Worldwide Pharmaceuticals Head William Burns said
You may also be interested in...
CMS’ Off-Label Coverage Decision For Colorectal Cancer Drugs Could Include Registries
The Centers for Medicare & Medicaid Services’ national coverage determination for oncologics, including Avastin and Erbitux, could be modeled on coverage for PET scans in Alzheimer’s patients, which includes trial registries. CMS expects to complete its coverage determination by Dec. 31.
Avastin Account Orders Double, Reorder Rate Improves To 80%
The number of accounts ordering the oncologic rose from 1,500 to more than 3,000 in the second quarter, with 80% of accounts placing reorders. Genentech says the majority of Avastin's sales come from the front-line setting.
Colorectal Cancer Drug Costs May Force Rationing – ASCO Presentation
Cost per patient has soared from $500 to $250,000 in past decade, Memorial-Sloan Kettering Research says. It would cost $7.5 bil. to treat all colorectal cancer patients unless some restraints are put in place.